Description

Therapeutic Segment of DIABOMIN TABLETS

• Glycemic Control & Anti Diabetes Drug

Generic Name of DIABOMIN TABLETS

• Sitagliptin + Metformin

Indications of DIABOMIN TABLETS

For the treatment of the following conditions

• For the treatment of type 2 diabetes mellitus in adults: As monotherapy in patients inadequately controlled by diet and exercise alone, and for whom metformin is inappropriate due to contraindications or intolerance.
• As dual oral therapy in combination with Metformin, in patients with insufficient glycemic control despite a maximally tolerated dose of
  monotherapy with Metformin.Sulfonylurea, in patients with insufficient glycemic control despite a maximally tolerated dose of a
  sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance.Thiazolidinedione, in patients with inadequate glycemic control, and for
  For whom is the use of a thiazolidinedione appropriate? As triple oral therapy in combination with Sulfonylurea and Metformin, when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control.Also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.

DIABOMIN WORKS:

Sitagliptin 50 mg in Diabomin works by being a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral medications used to treat type 2 diabetes.

The core mechanism of action involves enhancing the body’s natural ability to control blood sugar levels by increasing the amount of active incretin hormones

Detailed Mechanism of Action of Diabomin

Inhibition of DPP-4 Enzyme: Sitagliptin works by competitively inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). The DPP-4 enzyme normally breaks down naturally occurring gut hormones called incretins.
Increased Incretin Levels: By blocking the DPP-4 enzyme, sitagliptin leads to higher and prolonged levels of active incretin hormones in the bloodstream, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Enhanced Insulin Secretion: When blood glucose levels are normal or elevated, these increased incretin levels stimulate the pancreatic beta cells to produce and release more insulin.
Reduced Glucagon Secretion: GLP-1 also suppresses the release of glucagon from the pancreatic alpha cells. Glucagon is a hormone that signals the liver to produce more glucose (sugar).
Improved Glucose Control: The combined effect of increased insulin and decreased glucagon helps to drive blood glucose levels toward a normal range. This action is glucose-dependent, meaning it primarily works when blood sugar is high, which lowers the risk of hypoglycemia (very low blood sugar) compared to some other diabetes medications